Ambulatory monitoring of electrodermal activity (EDA) and Heart Rate Variability (HRV) for prediction of motor fluctuations in Parkinson’s Disease (PD)
Objective: To determine whether changes in EDA and HRV are associated with motor fluctuations in patients with PD Background: EDA and HRV are affected in…A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1
Objective: To investigate efficacy and safety of two doses of Opicapone (OPC) compared to placebo administered once daily for 14 to 15 weeks to Japanese…Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease
Objective: To evaluate efficacy, safety, and tolerability of supratherapeutic doses of apomorphine sublingual film (APL-130277; APL) in patients with Parkinson’s disease (PD) and “OFF” episodes.…An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2
Objective: To investigate the safety and efficacy of continuous treatment with 50 mg Opicapone (OPC) for 1 year after treatment with a placebo, 25 mg…Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis
Objective: To examine safety and tolerability of apomorphine sublingual film (APL-130277; APL) during maintenance treatment using pooled data from 4 clinical studies in patients with…Patient insights into the burden of OFF-episodes in Parkinson’s disease: Qualitative Interviews
Objective: Identify symptoms and impacts associated with OFF-episodes (OEs). Background: OFF-episodes are commonly experienced in patients with Parkinson’s disease (PD). Qualitative research into patients’ experience…Diplopia and visual complaints in non-demented patients with Parkinson disease: a Japanese single center cross-sectional survey
Objective: To investigate the characterization of diplopia and visual complaints including minor forms of hallucinations (mHals) in non-demented patients with Parkinson disease (PD). Background: Double…Analysis of Levodopa Content in Commercial Formulations of Mucuna pruriens Seeds Used in Integrative Treatment of Parkinson’s Disease
Objective: Objective: Formulations of Mucuna pruriens (MP) seed products are readily available through the internet and health food stores, and are used by some Parkinson's…Difference in perception of the wearing-off between patients and physicians in Parkinson’s disease
Objective: To explore if any inconsistency exists in the perception of the presence of wearing-off (WO) symptoms between patients and physicians in Parkinson’s disease (PD).…THOR 201: A Proof-of-Concept Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of L-dopa delivered by Impel’s Precision Olfactory Delivery (PODTM) to Parkinson’s Disease Patients in an OFF Episode (in the presence of Dopa Decarboxylase Inhibitor)
Objective: Impel NeuroPharma has developed the patient-friendly, self or caregiver actuatedPrecision Olfactory Delivery (IMPEL PODTM) device to achieve consistent upper nasal cavity drug delivery, rapid…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 26
- Next Page »